A novel orally bioavailable small molecule, ONC201 (initially called TRAIL-inducing compound 10, or TIC10), was identified as the first-in-class imipridone that was shown to have anti-tumor effects through continuous dual induction of the endogenous TRAIL tumor suppressor and its pro-apoptotic receptor DR5 [12]. This evidence concerns the gene TNFRSF10B and neoplasm.